CCM
ABUS icon

Coldstream Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Coldstream Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-284
Closed -$992 – 1117
2025
Q1 		$992 Buy
+284
New +$947 ﹤0.01% 3185

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return

Coldstream Capital Management's ABUS Position: Q2 2025 in Review

Coldstream Capital Management sold out of Arbutus Biopharma (ABUS) in Q2 2025, closing a stake of 284 shares — an estimated $992 sold.

Coldstream Capital Management first reported a position in ABUS in Q1 2025 and held it in 1 quarter. The position peaked at $992 in Q1 2025. 162 funds tracked by Wall St. Rank hold ABUS as of Q2 2025.

  • Coldstream Capital Management reported no remaining Arbutus Biopharma position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 284 Arbutus Biopharma shares in Q2 2025, an estimated $992.
  • Coldstream Capital Management first reported a position in Arbutus Biopharma in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Arbutus Biopharma position peaked at $992 in Q1 2025.
  • 162 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.